A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
Description
To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.